Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) have been given a consensus recommendation of “Buy” by the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $42.67.
A number of equities analysts have weighed in on the company. ValuEngine raised Portola Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, March 27th. BidaskClub downgraded Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, April 22nd. Zacks Investment Research cut Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 24th. Cowen restated a “buy” rating on shares of Portola Pharmaceuticals in a report on Wednesday, May 8th. Finally, Oppenheimer set a $42.00 price objective on Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, April 12th.
NASDAQ PTLA traded down $0.87 during trading on Friday, reaching $29.55. 835,535 shares of the company’s stock were exchanged, compared to its average volume of 992,779. The company has a market cap of $2.02 billion, a PE ratio of -5.90 and a beta of 2.35. The company has a quick ratio of 4.77, a current ratio of 4.81 and a debt-to-equity ratio of 5.15. Portola Pharmaceuticals has a fifty-two week low of $14.81 and a fifty-two week high of $45.60.
In related news, Director Hollings Renton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $34.45, for a total value of $172,250.00. Following the completion of the sale, the director now directly owns 14,000 shares in the company, valued at $482,300. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Mardi Dier sold 40,486 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $37.39, for a total value of $1,513,771.54. Following the completion of the sale, the chief financial officer now owns 66,733 shares of the company’s stock, valued at $2,495,146.87. The disclosure for this sale can be found here. Insiders own 4.60% of the company’s stock.
Several hedge funds have recently modified their holdings of PTLA. Fiera Capital Corp bought a new stake in shares of Portola Pharmaceuticals in the first quarter valued at approximately $53,590,000. William Blair Investment Management LLC boosted its stake in shares of Portola Pharmaceuticals by 41.7% in the first quarter. William Blair Investment Management LLC now owns 4,154,870 shares of the biopharmaceutical company’s stock valued at $144,174,000 after buying an additional 1,222,057 shares during the period. Norges Bank bought a new stake in shares of Portola Pharmaceuticals in the fourth quarter valued at approximately $11,465,000. Peregrine Capital Management LLC bought a new stake in shares of Portola Pharmaceuticals in the fourth quarter valued at approximately $10,626,000. Finally, Emerald Advisers LLC bought a new stake in shares of Portola Pharmaceuticals in the first quarter valued at approximately $14,058,000.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Further Reading: What is cost of equity?
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.